ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years
Tuomas Tammela
Matched on ORCID iD 0000-0003-3675-6961; OpenAlex author ID A5021977502; NIH RePORTER profile ID 11948169. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 3
- Labs led
- 1
- Collaborators
- 18
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper, 3 grants
Papers 4
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. Co-author DOI 10.1126/sciadv.aeh8973↗
- A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-24-0740↗
- Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. Last author DOI 10.1158/0008-5472.can-22-1742↗
- Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1920240117↗
Grants 3
- Identifying Genetic Vulnerabilities and Paracrine Interactions of the Basal Cell State in Pancreatic Cancer Organoids AWARD stephenson:2026-tuomas-tammela-identifying-genetic-vulnerabilities-and-
- Investigating hypoxia as a determinant of malignant fates in pancreas cancer R01CA290400↗
- Targeting stem-like cells and their niche in pancreatic cancer R37CA244911↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael Hemann · 1 shared grant, 2026 · strength 1.26
- Olivera Grbovic-Huezo · 3 shared papers, 2020–2024 · strength 0.39
- Paper A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-24-0740↗
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Anupriya Singhal · 2 shared papers, 2022–2024 · strength 0.29
- Michael T. Hemann · 1 shared paper, 2026 · strength 0.27
- Julia Fröse · 1 shared paper, 2026 · strength 0.27
- Matilda Holm · 2 shared papers, 2020–2022 · strength 0.22
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Kenneth L Pitter · 2 shared papers, 2020–2022 · strength 0.22
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Christine A. Iacobuzio–Donahue · 2 shared papers, 2020–2022 · strength 0.22
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Olca Baştürk · 1 shared paper, 2024 · strength 0.17
- Iok In Christine Chio · 1 shared paper, 2024 · strength 0.17
- Rona D. Yaeger · 1 shared paper, 2024 · strength 0.17
- Dana Pe'er · 1 shared paper, 2022 · strength 0.13
- Simon Joost · 1 shared paper, 2022 · strength 0.13
- Suhasini Joshi · 1 shared paper, 2020 · strength 0.10
- Gökçe Aşkan · 1 shared paper, 2020 · strength 0.10
- Caj H. Haglund · 1 shared paper, 2020 · strength 0.10
- Steven D Leach · 1 shared paper, 2020 · strength 0.10
- Rohit Chandwani · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.